



First European podium presentation at Congress of the German Society of Phlebology for Theraclions' Echopulse for varicose veins

- **Positive preliminary results from a trial of the first non-invasive approach to treatment of varicose veins of the lower limb**
- **Alfred Obermayer MD presented at the German Society of Phlebology (DGP) – Bielefeld (Germany) on September 27th**

Malakoff, October 15, 2018 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces today that Alfred Obermayer MD, principal investigator of the varicose vein treatment clinical trial in Austria, presented preliminary results at the prestigious Congress of the German Society of Phlebology in Bielefeld, attended by around 1200 participants. The study aims to assess echotherapy for this new indication in terms of feasibility, efficacy and tolerability.

“With around 500 000 vein procedures (stripping, endovenous, and sclerotherapy) performed annually, Germany is the biggest market in Europe. It also is the market where endovenous procedures are the most penetrated and covered by the health insurance companies.” says Anja Kleber, VP Marketing & Market Access. “This is why Echopulse’s first scientific varicose vein treatment presentation was unveiled in Germany.”

Three-month follow-up data were presented from cases targeting greater saphenous veins, accessory saphenous veins, perforator veins, recurrences (after surgery, foam therapy and endovenous methods) and refluxing stumps. The cases were feasible, no adjunctive methods of any kind were used during the study. No significant side effects were observed and no antithrombotic or anticoagulant drugs were administered.

“This new technique is the first non-invasive approach in the veins domain. Heat deposited for occluding an insufficient vein is transmitted percutaneously via high intensity focused ultrasound (HIFU). This means: no incision, no sterile field needed and the possibility to treat severe conditions – such as ulcers. The precision of the heat deposition allows treatment of very tortuous structures or recurrences that are difficult to treat surgically.” says Alfred Obermayer, MD – principal investigator and surgeon at St-Joseph Hospital in Vienna. “Taking into consideration my past experience with surgery, radiofrequency, laser and foam sclerotherapy approaches in this indication, I am extremely impressed by this new treatment approach which is globally very promising.”

“We are very satisfied with these early results in the first ever human study on veins with HIFU”, says Michel Nuta, MD, CMO and VP Veins Theraclion “This is the next era in the therapeutic domain for veins. Some spectacular results were observed in patients with a long medical history and poor results with previous treatments using other methods. The trial confirmed that our experience very accurately depositing heat in thousands of thyroid and breast fibroadenoma patients is reproducible in veins.”

“This is the first podium presentation in one of Europe’s largest vascular veins congress and the first after completing our registration study. Feedback from Dr Obermayer and his peers throughout the world make us confident that our technology will revolutionize the treatment of varicose veins. The non-invasive capability of echotherapy to treat tortuous structures, treat severe trophic cases and reoccurrences with an image-guided robotic device is a quantum leap forward compared to current therapeutic offerings. We aim to submit a dossier for both CE marking and FDA approval by the end of 2018. We will then aim at proposing this solution to key sites in Germany as this is our European showcase for thyroid and breast today.” says David Caumartin, CEO Theraclion.

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 23 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com

Theraclion is listed on Euronext Growth Paris
PEA-PME eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402



Contacts:

Theraclion

David Caumartin

CEO

Tel.: +33 (0)1 55 48 90 70

david.caumartin@theraclion.com